New Trials = New Path

I see all the current trials as being newly formatted, creating a new path.

I believe that with good US Pediatric results, and FDA approval Resapp will be in high demand by US Health Insurance Funds to reduce hospital and face to face doctor visits by recommending a Telehealth visit.

I see Health Insurance companies will be wanting a FDA approved respiratory diagnosis on all their telehealth platforms to

(a) to prevent expensive face to face visits to a doctor or hospital

(a) to prevent expensive face to face visits to a doctor or hospital

(a) to prevent expensive face to face visits to a doctor or hospital

GLTA
MB